verapamil and atorvastatin

verapamil has been researched along with atorvastatin in 25 studies

Research

Studies (25)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (48.00)	29.6817
2010's	11 (44.00)	24.3611
2020's	2 (8.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Boyd, RA; Randinitis, EJ; Reyner, EL; Stern, RH; Stewart, BH; Whitfield, L; Wu, X; Zegarac, EA	1
Stewart, BH; Whitfield, LR; Wu, X	1
Grand-Perret, T; Issandou, M	1
Jacobson, TA	1
Babita, K; Tiwary, AK	1
Hatipoglu, SE; Iltimur, K; Tacar, O; Tuncer, CM	1
Chang, KS; Choi, DH; Choi, JS; Han, HK; Hong, SP	1
Choi, DH; Choi, JS; Shin, WG	1
Srinivas, NR	3
Rao, N	1
Benet, LZ; Estudante, M; Maya, M; Morais, JG; Soveral, G	1
Agarwal, M; Dash, RP; Ellendula, B; Nivsarkar, M	1
Caran, T; Cibicek, N; Cibickova, L; Dobias, M; Ondra, P; Vorisek, V	1
Liu, L; Liu, X; Tang, X; Wang, S; Xu, J; Yang, T; Zhang, J	1
Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C	1
Abdulaziz, O; Ahmad, S; Ali, N; Ali, W; Aljuaid, A; Allahyani, M; Almehmadi, M; Alsaiari, AA; Ullah, A	1

Reviews

1 review(s) available for verapamil and atorvastatin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

3 trial(s) available for verapamil and atorvastatin

Article	Year
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. Journal of clinical pharmacology, 2000, Volume: 40, Issue:1 Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Humans; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Time Factors; Verapamil	2000
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. The American journal of cardiology, 2004, Nov-01, Volume: 94, Issue:9 Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil	2004
Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. European journal of clinical pharmacology, 2008, Volume: 64, Issue:5 Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Drug Interactions; Heptanoic Acids; Humans; Male; Pyrroles; Verapamil	2008

Other Studies

21 other study(ies) available for verapamil and atorvastatin

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7 Topics: Glutathione; Pharmacology; Sulfur Radioisotopes	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:8 Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters	2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharmaceutical research, 2000, Volume: 17, Issue:2 Topics: Acetic Acid; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoic Acid; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carbon Radioisotopes; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Carboxylic Acids; Carrier Proteins; Cell Polarity; Cyclosporine; Drug Interactions; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indicators and Reagents; Ionophores; Niacin; Protons; Pyrroles; Verapamil; Vinblastine	2000
Multidrug resistance P-glycoprotein is not involved in cholesterol esterification. Biochemical and biophysical research communications, 2000, Dec-20, Volume: 279, Issue:2 Topics: Acridines; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cholesterol Esters; DNA-Binding Proteins; Fluoresceins; Fluorescent Dyes; Heptanoic Acids; Humans; Isoquinolines; Kinetics; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Probenecid; Progesterone; Pyrroles; Sterol O-Acyltransferase; Tetrahydroisoquinolines; Tumor Cells, Cultured; Verapamil	2000
Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa. Current drug delivery, 2004, Volume: 1, Issue:4 Topics: Administration, Cutaneous; Animals; Anticholesteremic Agents; Antiparkinson Agents; Atorvastatin; beta-Alanine; Calcium Channel Blockers; Calcium Chloride; Cholesterol; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; In Vitro Techniques; Levodopa; Male; Pyrroles; Rats; Rats, Wistar; Serine C-Palmitoyltransferase; Skin; Sphingosine; Time Factors; Verapamil	2004
Single coronary artery with retroaortic course. An unusual origin of right Valsalva sinus. Saudi medical journal, 2006, Volume: 27, Issue:7 Topics: Adult; Aspirin; Atorvastatin; Chest Pain; Coronary Vessel Anomalies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Radiography; Sinus of Valsalva; Vasodilator Agents; Verapamil	2006
Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats. Biopharmaceutics & drug disposition, 2008, Volume: 29, Issue:1 Topics: Administration, Oral; Analysis of Variance; Animals; Area Under Curve; Atorvastatin; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Male; Metabolic Clearance Rate; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil	2008
Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. European journal of clinical pharmacology, 2008, Volume: 64, Issue:11 Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Pyrroles; Verapamil	2008
Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied? Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:3 Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Drug Design; Drug Interactions; Heptanoic Acids; Kinetics; Pharmacology, Clinical; Pyrroles; Verapamil	2009
Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin. Journal of clinical pharmacology, 2009, Volume: 49, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Purines; Pyrroles; Rifampin; Verapamil	2009
Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin. Journal of clinical pharmacology, 2011, Volume: 51, Issue:5 Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Anion Transporters; Purines; Pyrroles; Research Design; Rifampin; Verapamil	2011
Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil. Molecular pharmaceutics, 2013, Nov-04, Volume: 10, Issue:11 Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Heptanoic Acids; Intestinal Absorption; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil	2013
Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies. European journal of pharmacology, 2015, Nov-15, Volume: 767 Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Catechin; Diabetes Mellitus, Experimental; Disease Progression; Ileum; Intestinal Absorption; Male; Rats; Sodium-Potassium-Exchanging ATPase; Verapamil	2015
Multi-drug intoxication fatality involving atorvastatin: A case report. Forensic science international, 2015, Volume: 257 Topics: Acute Kidney Injury; Aged; Alcoholics; Anthraquinones; Anti-Inflammatory Agents; Antihypertensive Agents; Atorvastatin; Drug Overdose; Female; Forensic Toxicology; Gastrointestinal Contents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Piperazines; Rhabdomyolysis; Suicide; Vasodilator Agents; Verapamil	2015
Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes. Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:2 Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Diclofenac; Humans; Kinetics; Microsomes, Liver; Midazolam; Protein Isoforms; Testosterone; Tolbutamide; Verapamil; Warfarin	2019
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Verapamil	2020
Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon. Medicina (Kaunas, Lithuania), 2023, May-25, Volume: 59, Issue:6 Topics: Amlodipine; Animals; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Potassium Chloride; Rabbits; Rats; Rats, Wistar; Vasodilator Agents; Verapamil	2023